biostudies-literatureUnknown8(20)Camus V<h4>Abstract</h4>Tafasitamab plus lenalidomide (TAFA-LEN) treatment relevance pre- or post-anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is debated. We analyzed patients with large B-cell lymphoma in the DESCAR-T registry treated with axi[1]cel or tisa-cel in ≥3rd line and TAFA-LEN before (n = 15, "TL-pre-CAR-T" set) or directly after (n = 52, "TL-post-CAR-T" set) CAR T-cell therapy. We compared TAFA-LEN v. other treatments using inverse probability weighting in the TL-post-CAR[1]T set. In the TL-post-CAR-T set, the median progression-free survival (mPFS), overall survival (mOS), and duration of response (mDOR) since the first treatment for progression (mPFS2/mOS2/mDOR2) were 3, 4.7, and 8.1 months, respectively. The best overall response rate (bORR) and best complete response rBlood advances5371-5381https://www.ebi.ac.uk/biostudies/studies/S-EPMC11568786biostudies-literatureOutcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy.PMC11568786Carras SCastilla-Llorente CChauchet AAbraham JHouot RDrieu La Rochelle LCasasnovas OMarquet ATounes LOberic LDamaj GLBailly SDecroocq JJardin FGuidez SDupont VFornecker LMLemonnier FHerbaux CHermine OMorschhauser FLe Gouill SSesques PCampidelli AJoris MBrisou GBouabdallah KPaillassa JChoquet STessoulin BKrzisch DCamus VfalseOutcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy.<h4>Abstract</h4>Tafasitamab plus lenalidomide (TAFA-LEN) treatment relevance pre- or post-anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is debated. We analyzed patients with large B-cell lymphoma in the DESCAR-T registry treated with axi[1]cel or tisa-cel in ≥3rd line and TAFA-LEN before (n = 15, "TL-pre-CAR-T" set) or directly after (n = 52, "TL-post-CAR-T" set) CAR T-cell therapy. We compared TAFA-LEN v. other treatments using inverse probability weighting in the TL-post-CAR[1]T set. In the TL-post-CAR-T set, the median progression-free survival (mPFS), overall survival (mOS), and duration of response (mDOR) since the first treatment for progression (mPFS2/mOS2/mDOR2) were 3, 4.7, and 8.1 months, respectively. The best overall response rate (bORR) and best complete response r2024-01-01T00:00:00Z2024 Oct2026-06-03T03:12:10.748Z2025-04-06T22:45:57.644ZS-EPMC115687863916362010.1182/bloodadvances.2024013726